Skip to main content
AUPH
NASDAQ Life Sciences

CEO Kevin Tang Buys $12.4M in Aurinia Pharmaceuticals Stock

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$15.39
Mkt Cap
$1.979B
52W Low
$7.285
52W High
$16.88
Market data snapshot near publication time

Summary

Aurinia Pharmaceuticals CEO Kevin Tang made a significant open market purchase of over $12.4 million in company stock, demonstrating strong confidence in the company's future following recent strategic moves and positive financial results.


Key Events

  • Significant CEO Stock Purchase

    Kevin Tang, CEO, Director, and 10% Owner, purchased 814,606 common shares for a total of $12,455,227 in open market transactions between May 29 and June 2, 2026.

  • Strong Vote of Confidence

    This substantial investment by the new CEO, appointed in March 2026, signals strong conviction in the company's prospects following recent strategic acquisitions and positive Q1 financial results.

  • Contrasting Insider Activity

    The purchase occurs amidst recent Form 144 filings by other affiliates and the former CEO indicating intent to sell shares, making Tang's buy a notable counter-signal.

  • Derivative Position Taken

    Tang also acquired 10,000 short put options for $16,500, with a strike price of $15 and an expiration in January 2027, indicating a potential obligation to acquire 1,000,000 shares if the stock price falls below the strike.


Analysis

Aurinia Pharmaceuticals' new CEO, Kevin Tang, made a substantial open market purchase of over $12.4 million in company stock. This significant investment, representing 0.63% of the company's market cap, is a strong vote of confidence from a key insider who also serves as a Director and 10% owner. The purchase follows his appointment as CEO in March 2026, the strategic acquisition of Kezar Life Sciences, and strong Q1 2026 financial results, and stands in contrast to recent Form 144 filings by other affiliates and the former CEO indicating intent to sell shares.

At the time of this filing, AUPH was trading at $15.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Jun 02, 2026, 9:54 PM EDT
Filing Type: 4
Importance Score:
8
AUPH
Jun 02, 2026, 4:13 PM EDT
Filing Type: 144
Importance Score:
9
AUPH
May 11, 2026, 4:11 PM EDT
Filing Type: 144
Importance Score:
8
AUPH
May 11, 2026, 4:10 PM EDT
Filing Type: 144
Importance Score:
7
AUPH
May 11, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
7
AUPH
May 07, 2026, 8:23 AM EDT
Filing Type: 10-Q
Importance Score:
8
AUPH
May 07, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
8
AUPH
May 07, 2026, 8:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
AUPH
Apr 21, 2026, 4:31 PM EDT
Filing Type: DEF 14A
Importance Score:
8
AUPH
Apr 03, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
8